United Therapeutics (NASDAQ:UTHR) had its price objective hoisted by research analysts at Credit Suisse Group from $113.00 to $121.00 in a report released on Thursday, The Fly reports. The firm presently has an “outperform” rating on the biotechnology company’s stock. Credit Suisse Group’s target price would indicate a potential upside of 16.13% from the stock’s previous close.
Several other research firms have also weighed in on UTHR. Zacks Investment Research lowered shares of United Therapeutics from a “hold” rating to a “sell” rating and set a $93.00 price objective on the stock. in a research note on Thursday, January 2nd. Bank of America began coverage on shares of United Therapeutics in a research note on Tuesday, December 3rd. They issued an “underperform” rating and a $80.00 price objective on the stock. Wedbush reiterated a “buy” rating and issued a $237.00 price objective on shares of United Therapeutics in a research note on Monday, February 3rd. ValuEngine lowered shares of United Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, February 4th. Finally, BidaskClub upgraded shares of United Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and five have issued a buy rating to the company’s stock. United Therapeutics has an average rating of “Hold” and an average target price of $116.17.
United Therapeutics stock opened at $104.19 on Thursday. The firm has a market cap of $4.57 billion, a PE ratio of -48.01, a P/E/G ratio of -1.57 and a beta of 1.01. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.91 and a current ratio of 4.11. The firm’s 50 day moving average price is $92.81 and its two-hundred day moving average price is $87.21. United Therapeutics has a twelve month low of $74.31 and a twelve month high of $128.94.
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.
See Also: Percentage Decliners
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.